Search Articles — Sudonull

https://sudonull.com/owasp-top-10-explained-what-it-is-why-it-matters

Learn what is the OWASP Top 10 and why does it matter for secure coding. A developer's guide to web app vulnerabilities, risks, and practical defense strategies.

https://sudonull.com/llm-security-evolution-from-firewall-to-gaf-in-depth-analysis

How modern threats to LLM require multi-level protection. We analyze incidents of 2025-2026 and the transition to Generative Application Firewall. Learn how to protect AI systems.

https://sudonull.com/web-application-vulnerabilities-xss-sqli-enumeration

Breakdown of top-3 vulnerabilities in web: user enumeration, XSS, SQL injections. Fix methods for developers: prepared statements, encoding. In-depth pentest guide.

https://sudonull.com/opc-ua-in-mfc-integration-of-open62541

How to integrate OPC UA into an MFC application in C++ with open62541. Connecting to Siemens S7, security, subscriptions, working with SQL Server.

https://sudonull.com/aliro-protocol-digital-keys-standard-for-smart-home

Detailed analysis of the Aliro protocol — a new standard for access control in smart homes. Learn about the principles of operation, security, and practical application.

https://ymaho.com/pediatric-dovato-ema-approves-application-for-hiv-therapy

EMA validated the application for pediatric Dovato (dolutegravir/lamivudine) for children from 2 years old. Learn how two-drug therapy is changing HIV treatment standards.

https://ymaho.com/ema-accepted-the-application-for-dovato-for-children-with-hiv

EMA validated the application for the use of Dovato in children from 3 months with HIV. Learn how this will change pediatric therapy and strengthen ViiV's position. Read the detailed analysis.

https://ymaho.com/pediatric-dovato-viiv-application-and-geopolitics-of-the-hiv-market

ViiV has submitted applications to the FDA and EMA for dispersible Dovato tablets for children. We analyze the strategy, patents, and implications. Find out who will win.

https://ymaho.com/study-of-the-ottava-robot-forte-results-and-fda-application

Scientists have completed the pivotal study of the Ottava robot (FORTE) and are preparing an FDA application. Learn about clinical data, zero conversions, and market prospects for robotic surgery.

https://ymaho.com/gene-therapy-for-deafness-otarmeni-ema-accelerated-review-2026

EMA accepted the application for gene therapy otarmeni for the treatment of hereditary deafness OTOF. Market analysis, forecasts, price and implications for the industry. Read.

https://ymaho.com/spacex-ipo-filing-for-75-billion-and-valuation-of-1-75-trillion

SpaceX filed an application for the largest IPO in history on Nasdaq up to $75 billion. Valuation $1.75 trillion, listing in June 2026. Analysis of the record, consequences and hidden details. Read more.

https://ymaho.com/intellia-crispr-therapy-fda-filing-for-lonvo-z-for-hae

Intellia has filed the world's first application for an in vivo CRISPR therapy, lonvo-z, for hereditary angioedema (HAE). 87% reduction in attacks, 62% attack-free. Risk, market, and forecast analysis. Read.

https://lrivo.com/linlithgow-rose-spfl-play-off-exclusion-due-to-licence

Linlithgow Rose miss SPFL play-offs after SFA bronze licence application declined. Brora Rangers face Edinburgh City in final. Learn why.

https://ymaho.com/ai-for-early-diagnosis-of-gallbladder-cancer-accuracy-92-97

PGIMER AI model analyzes ultrasound and detects gallbladder cancer at an early stage. Free application for hospitals. Data from The Lancet. Learn more.

https://ymaho.com/ipo-of-uznif-uzbekistan-s-entry-onto-the-london-stock-exchange-for-1-95-billion

Dual IPO of Uzbekistan's National Fund for $1.95 billion in Tashkent and London. GDR price — $25. Submit your application by May 12 and learn the placement details.